Pemphigus is rare, affecting about 5.2 per 100,000 people, but it disproportionately strikes older adults: the median age at pemphigus vulgaris presentation is about 71, and patients 65 and older face an adjusted hazard ratio of 5.9 for five-year mortality and 4.2 for ten-year mortality compared with younger patients. In this population, the leading causes of death are not the blisters themselves but treatment-related complications, including pneumonia, septicemia, and cardiovascular events driven largely by high-dose corticosteroid exposure, while first-line rituximab markedly reduces this harm. Recognizing pemphigus early and steering treatment away from prolonged high-dose steroids is among the highest-value clinical actions a care team can take.
AAVBC's Pemphigus Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity across pemphigus subtypes, drug-induced, and paraneoplastic disease, HCC/RAF V28 mapping, diagnostic thresholds using the 2020 International Consensus and PDAI, MEAT documentation standards, guideline-aligned treatment escalation centered on first-line rituximab, medication safety, comorbidity screening for infection and steroid-related complications, and referral and follow-up timing. Grounded in 2020 International Consensus and EDF-EADV guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize pemphigus early and limit corticosteroid-related harm, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of pemphigus — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Pemphigus is rare, affecting about 5.2 per 100,000 people, but it disproportionately strikes older adults: the median age at pemphigus vulgaris presentation is about 71, and patients 65 and older face an adjusted hazard ratio of 5.9 for five-year mortality and 4.2 for ten-year mortality compared with younger patients. In this population, the leading causes of death are not the blisters themselves but treatment-related complications, including pneumonia, septicemia, and cardiovascular events driven largely by high-dose corticosteroid exposure, while first-line rituximab markedly reduces this harm. Recognizing pemphigus early and steering treatment away from prolonged high-dose steroids is among the highest-value clinical actions a care team can take.
AAVBC's Pemphigus Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity across pemphigus subtypes, drug-induced, and paraneoplastic disease, HCC/RAF V28 mapping, diagnostic thresholds using the 2020 International Consensus and PDAI, MEAT documentation standards, guideline-aligned treatment escalation centered on first-line rituximab, medication safety, comorbidity screening for infection and steroid-related complications, and referral and follow-up timing. Grounded in 2020 International Consensus and EDF-EADV guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize pemphigus early and limit corticosteroid-related harm, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of pemphigus — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
